<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Mor-Vaknin N</submitter><funding>NIDDK NIH HHS</funding><funding>NIAID NIH HHS</funding><funding>Rheumatology Research Foundation</funding><funding>National Institutes of Health</funding><funding>Center for Scientific Review</funding><funding>NIAMS NIH HHS</funding><pagination>594-605</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5876119</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>70(4)</volume><pubmed_abstract>&lt;h4>Objective&lt;/h4>The nuclear oncoprotein DEK is an autoantigen associated with juvenile idiopathic arthritis (JIA), especially the oligoarticular subtype. DEK is a secreted chemotactic factor. Abundant levels of DEK and DEK autoantibodies are found in inflamed synovium in JIA. We undertook this study to further characterize the nature of DEK autoantibodies in screening serum samples from 2 different cohorts that consisted mostly of patients with JIA.&lt;h4>Methods&lt;/h4>DEK autoantibody levels were analyzed in sera from 33 JIA patients, 13 patients with other inflammatory conditions, and 11 healthy controls, as well as in 89 serum samples from JIA patients receiving anti-tumor necrosis factor (anti-TNF) therapy. Recombinant His-tagged full-length DEK protein (1-375 amino acids [aa]) and the 18</pubmed_abstract><journal>Arthritis &amp; rheumatology (Hoboken, N.J.)</journal><pubmed_title>High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy.</pubmed_title><pmcid>PMC5876119</pmcid><funding_grant_id>K01 AR055620</funding_grant_id><funding_grant_id>T32 AI007413</funding_grant_id><funding_grant_id>R01 AI062248</funding_grant_id><funding_grant_id>R01 DK109188</funding_grant_id><funding_grant_id>R01 AI087128</funding_grant_id><funding_grant_id>R01‐AI‐087128</funding_grant_id><funding_grant_id>R03‐AR‐056748‐01</funding_grant_id><funding_grant_id>K01‐AR‐055620</funding_grant_id><funding_grant_id>R01‐DK‐109188</funding_grant_id><funding_grant_id>R03 AR056748</funding_grant_id><funding_grant_id>R01‐AI‐062248</funding_grant_id><funding_grant_id>P60 AR047784</funding_grant_id><funding_grant_id>T32 AR007080</funding_grant_id><pubmed_authors>Markovitz DM</pubmed_authors><pubmed_authors>Kimura Y</pubmed_authors><pubmed_authors>Passo MH</pubmed_authors><pubmed_authors>Cassidy EA</pubmed_authors><pubmed_authors>Rivas M</pubmed_authors><pubmed_authors>Jung LK</pubmed_authors><pubmed_authors>Beukelman T</pubmed_authors><pubmed_authors>Mehta J</pubmed_authors><pubmed_authors>Edelheit BS</pubmed_authors><pubmed_authors>Zhao L</pubmed_authors><pubmed_authors>Gottlieb BS</pubmed_authors><pubmed_authors>Mohan S</pubmed_authors><pubmed_authors>Johnson A</pubmed_authors><pubmed_authors>Adams BS</pubmed_authors><pubmed_authors>Lovell DJ</pubmed_authors><pubmed_authors>Spalding SJ</pubmed_authors><pubmed_authors>Huang B</pubmed_authors><pubmed_authors>Onel K</pubmed_authors><pubmed_authors>Mau T</pubmed_authors><pubmed_authors>Prahalad S</pubmed_authors><pubmed_authors>Legendre M</pubmed_authors><pubmed_authors>Giannini EH</pubmed_authors><pubmed_authors>Olson JC</pubmed_authors><pubmed_authors>Yuanfan Y</pubmed_authors><pubmed_authors>Mor-Vaknin N</pubmed_authors><pubmed_authors>Morris PW</pubmed_authors><pubmed_authors>Shishov M</pubmed_authors></additional><is_claimable>false</is_claimable><name>High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy.</name><description>&lt;h4>Objective&lt;/h4>The nuclear oncoprotein DEK is an autoantigen associated with juvenile idiopathic arthritis (JIA), especially the oligoarticular subtype. DEK is a secreted chemotactic factor. Abundant levels of DEK and DEK autoantibodies are found in inflamed synovium in JIA. We undertook this study to further characterize the nature of DEK autoantibodies in screening serum samples from 2 different cohorts that consisted mostly of patients with JIA.&lt;h4>Methods&lt;/h4>DEK autoantibody levels were analyzed in sera from 33 JIA patients, 13 patients with other inflammatory conditions, and 11 healthy controls, as well as in 89 serum samples from JIA patients receiving anti-tumor necrosis factor (anti-TNF) therapy. Recombinant His-tagged full-length DEK protein (1-375 amino acids [aa]) and the 18</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 Apr</publication><modification>2026-06-03T17:49:41.026Z</modification><creation>2019-03-26T23:31:11Z</creation></dates><accession>S-EPMC5876119</accession><cross_references><pubmed>29287303</pubmed><doi>10.1002/art.40404</doi></cross_references></HashMap>